Drug: Ixempra (ixabepilone)
Company: Bristol-Myers Squibb
Approval Date: October 16, 2007
Scoop: Ixempra gained FDA approval as a stand-alone treatment for patients who've failed other chemotherapy and for use with Roche's Xeloda in patients whose cancer has spread. Ixempra is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones. A treatment course of Ixempra is expected to cost $18,000 to $23,000, and is expected to earn BMS $500 million in annual sales by 2010.
BMS cancer med could earn $500M. Report